Maximum tolerated dose

Phase 1Biologic

MMedical College of Wisconsin

Maximum tolerated dose is one of 86 biologic programs targeting Ovarian Cancer. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Ovarian CancerRecruiting

Multiple MyelomaRecruiting

Ovarian CancerPhase 1

Recruiting

Multiple MyelomaPhase 1

Recruiting

Competition

Competitive Landscape

259 competitors in Multiple Myeloma

#DrugCompanyPhaseTrials

TALVEY

Johnson & Johnson

Phase 3

22 2

Venclexta

AbbVie

Phase 3

17 3

Vepesid

AAvyxa

Phase 3

17 4

BLENREP

GGlaxo Dba Glaxosmithkline

Phase 3

11 5

Platinol

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Phase 3

9 6

Sylvant

RRECORDATI GROUP

Phase 3

8 7

Linvoseltamab

Regeneron

Phase 3

9 8

Velcade

Takeda

Phase 3

28 9

Opioid

Johnson & Johnson

Phase 3

1 10

Adriamycin

HHRYZ Biotech Co.

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2028

Phase 1Recruiting

Triple Negative Breast Cancer (TNBC)

NCT07652242

Q2 2029

Phase 1Recruiting

Multiple Myeloma

NCT05976555

Q4 2029

Phase 1Recruiting

Ovarian Cancer

NCT06976892

Clinical

Trials by Indication[1]

Ovarian Cancer1 trial

Investigating Idetrexed and Olaparib in Patients With Ovarian Cancer

Recruiting·IInstitute of Cancer Research, United Kingdom·Phase 1·NCT06976892·33 enrolled

Triple Negative Breast Cancer (TNBC)1 trial

A Phase 1, Multicenter, Open-label, First-in-Human Study of ITI-5000 (Self-Amplifying RNA Vaccine) Alone and in Combination With Standard of Care Adjuvant Therapy in Participants With Stage II-III Triple-Negative Breast Cancer (TNBC)

Recruiting·IImmunomic Therapeutics, Inc.·Phase 1·NCT07652242·60 enrolled

Multiple Myeloma1 trial

Phase I Study of BCMA-TGF-BETA Insensitive Armored CAR T Cells in Patients With Relapsed and/or Refractory Multiple Myeloma

Recruiting·MMedical College of Wisconsin·Phase 1·NCT05976555·30 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Maximum tolerated dose. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Maximum tolerated dose compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Maximum tolerated dose. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Medical College of Wisconsin company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 1[1]
Company: MMedical College of Wisconsin

Maximum tolerated dose

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2028

Q2 2029

Q4 2029

Trials by Indication[1]

Ovarian Cancer1 trial

Triple Negative Breast Cancer (TNBC)1 trial

Multiple Myeloma1 trial

References

Drug Info

Quick Facts

Related News